Why Attend the MASH Drug Development Summit?
Building upon the latest scientific advancements and evolving understanding of MASH pathogenesis and clinical trial progress the summit will dissect the future of MASH drug discovery, development, and clinical application.
Understand the varying mechanisms of action being utilized to develop MASH drugs and unlock the potential of precisely targeted therapies for enhanced efficacy for heterogenous patient populations
Advance the integration of non-invasive biomarkers into MASH drug development, exploring their utility from early diagnosis to monitoring treatment response, to accelerate development pathways and reduce reliance on invasive procedures
Optimize the design of clinical trials for MASH therapies, addressing challenges in patient stratification, endpoint selection, and real-world evidence integration, to accelerate drug approval and ensure robust clinical outcomes
This is your opportunity to be at the forefront of MASH drug development at this critical endeavor as the therapeutic potential for liver health expands, accelerating the development of life-changing treatments for millions affected globally.
Join Your Peers to:
Learn cutting-edge strategies for identifying and stratifying MASH patient populations, to account for the disease's heterogeneity and optimize study design for more impactful and successful clinical outcomes
Explore the latest advancements in non-invasive diagnostic tools, including cutting-edge blood-based biomarkers and imaging technologies to provide patient-friendly and more accurate alternatives to traditional liver biopsies to enhance the early detection and accurate disease characterization during MASH diagnosis, prognosis and monitoring
Discuss the potential for strategic design and practical implementation of combination and sequential therapies to develop multifaceted treatment approaches that optimize synergistic effects to effectively address the complex heterogeneity of MASH
Discover innovative cell-specific drug delivery methods and a diverse range of novel mechanisms of action, including inflammatory modulation, siRNA approaches, and FGF21 signaling to directly deliver therapeutic agents to specific liver cell types to target underlying disease drivers and minimize off-target effects
Gain insights into the unique biological actions of GLP-1 receptor agonists to review their compelling clinical evidence in MASH and explore their expanded role to identify comprehensive therapeutic avenues for MASH patients
Explore the Full Event Guide
- 60+ MASH Scientists & Drug Development Experts Sharing Groundbreaking Research & Strategies
- 1 Pre-Conference Combination & Sequential Therapy Day
- 10+ Hours of Networking with 60+ Likeminded MASH-Focused Peers
Attending Companies Include:
Don't Just Take Our Word for It...
"The meeting was an excellent conference. It was a highly informative and interactive meeting. The speakers presented cutting edge approaches for novel treatments for obesity and NASH. There was plenty of time for discussions and networking”
CSO, Mitotherapeutix CSO, Mitotherapeutix
“Good selection of talks covering the latest data and trends in MASH and obesity. Good speakers. Small intimate setting, opportunities for networking’’
Senior Director, Paratus Sciences
